Skip to main content

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Terminated · Not applicable · NCT06572839

Conditions: Diabetic Foot Ulcer

At a glance

Research payments reported, 2025
$627,676
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
74

About the trial

Sponsor
Capsicure, LLC
Tested
Amnio-Maxx (other)
Dates
Started 2024-10-25; completion 2026-05-01
Results posted
Not yet

This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers

From ClinicalTrials.gov, last updated 2026-05-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Royal Biologics, Inc. reported $627,676 in research payments for this study in 2025 (64 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Cole Collaborative Consulting, LLC $180,000
  • Dp Bell Consulting, LLC $120,000
  • North PArk Podiatry $118,575
  • Solutions Medical $104,445
  • Symphony Research $38,366
  • Evolution Research $26,975
  • Curalta $15,345
  • Quality Care $12,250
  • Medcentris $10,585
  • West Georga $1,135

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.